Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
GNMK's Cash to Debt is ranked higher than
84% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. GNMK: No Debt )
GNMK' s 10-Year Cash to Debt Range
Min: 8.53   Max: No Debt
Current: No Debt

Equity to Asset 0.87
GNMK's Equity to Asset is ranked higher than
89% of the 450 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. GNMK: 0.87 )
GNMK' s 10-Year Equity to Asset Range
Min: 0.67   Max: 0.92
Current: 0.87

0.67
0.92
F-Score: 4
Z-Score: 20.68
M-Score: -3.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -149.40
GNMK's Operating margin (%) is ranked higher than
52% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 5.50 vs. GNMK: -149.40 )
GNMK' s 10-Year Operating margin (%) Range
Min: -4488.56   Max: -106.95
Current: -149.4

-4488.56
-106.95
Net-margin (%) -147.99
GNMK's Net-margin (%) is ranked higher than
53% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. GNMK: -147.99 )
GNMK' s 10-Year Net-margin (%) Range
Min: -4383.77   Max: -107.98
Current: -147.99

-4383.77
-107.98
ROE (%) -39.80
GNMK's ROE (%) is ranked higher than
55% of the 449 Companies
in the Global Medical Devices industry.

( Industry Median: 5.02 vs. GNMK: -39.80 )
GNMK' s 10-Year ROE (%) Range
Min: -158.05   Max: -40.63
Current: -39.8

-158.05
-40.63
ROA (%) -35.40
GNMK's ROA (%) is ranked higher than
56% of the 481 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. GNMK: -35.40 )
GNMK' s 10-Year ROA (%) Range
Min: -115.7   Max: -35.46
Current: -35.4

-115.7
-35.46
ROC (Joel Greenblatt) (%) -439.50
GNMK's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 480 Companies
in the Global Medical Devices industry.

( Industry Median: 6.67 vs. GNMK: -439.50 )
GNMK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2957.74   Max: -441.8
Current: -439.5

-2957.74
-441.8
Revenue Growth (3Y)(%) 44.20
GNMK's Revenue Growth (3Y)(%) is ranked higher than
97% of the 344 Companies
in the Global Medical Devices industry.

( Industry Median: 4.90 vs. GNMK: 44.20 )
GNMK' s 10-Year Revenue Growth (3Y)(%) Range
Min: -22.3   Max: 52.5
Current: 44.2

-22.3
52.5
EBITDA Growth (3Y)(%) -20.80
GNMK's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. GNMK: -20.80 )
GNMK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.4   Max: -20.8
Current: -20.8

-63.4
-20.8
EPS Growth (3Y)(%) -20.30
GNMK's EPS Growth (3Y)(%) is ranked higher than
68% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. GNMK: -20.30 )
GNMK' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.8   Max: -20.3
Current: -20.3

-62.8
-20.3
» GNMK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GNMK Guru Trades in

GNMK Guru Trades in

GNMK Guru Trades in

Q2 2013

GNMK Guru Trades in Q2 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GNMK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.20
GNMK's P/B is ranked higher than
60% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 4.16 vs. GNMK: 6.20 )
GNMK' s 10-Year P/B Range
Min: 1.61   Max: 10.43
Current: 6.2

1.61
10.43
P/S 17.54
GNMK's P/S is ranked higher than
57% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 3.75 vs. GNMK: 17.54 )
GNMK' s 10-Year P/S Range
Min: 9.44   Max: 24.96
Current: 17.54

9.44
24.96
EV-to-EBIT -11.14
GNMK's EV-to-EBIT is ranked lower than
54% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 68.02 vs. GNMK: -11.14 )
GNMK' s 10-Year EV-to-EBIT Range
Min: -21.3   Max: -0.3
Current: -11.14

-21.3
-0.3
Current Ratio 7.33
GNMK's Current Ratio is ranked higher than
90% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 2.58 vs. GNMK: 7.33 )
GNMK' s 10-Year Current Ratio Range
Min: 3.19   Max: 14.02
Current: 7.33

3.19
14.02
Quick Ratio 7.20
GNMK's Quick Ratio is ranked higher than
92% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. GNMK: 7.20 )
GNMK' s 10-Year Quick Ratio Range
Min: 3.15   Max: 13.78
Current: 7.2

3.15
13.78
Days Inventory 47.42
GNMK's Days Inventory is ranked higher than
94% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 157.38 vs. GNMK: 47.42 )
GNMK' s 10-Year Days Inventory Range
Min: 47.02   Max: 90.13
Current: 47.42

47.02
90.13
Days Sales Outstanding 36.33
GNMK's Days Sales Outstanding is ranked higher than
83% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 78.80 vs. GNMK: 36.33 )
GNMK' s 10-Year Days Sales Outstanding Range
Min: 38.08   Max: 96.52
Current: 36.33

38.08
96.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.20
GNMK's Price/Net Cash is ranked higher than
93% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. GNMK: 8.20 )
GNMK' s 10-Year Price/Net Cash Range
Min: 1.98   Max: 13.27
Current: 8.2

1.98
13.27
Price/Net Current Asset Value 7.90
GNMK's Price/Net Current Asset Value is ranked higher than
90% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. GNMK: 7.90 )
GNMK' s 10-Year Price/Net Current Asset Value Range
Min: 1.91   Max: 11.04
Current: 7.9

1.91
11.04
Price/Tangible Book 6.60
GNMK's Price/Tangible Book is ranked higher than
69% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 6.96 vs. GNMK: 6.60 )
GNMK' s 10-Year Price/Tangible Book Range
Min: 1.64   Max: 8.34
Current: 6.6

1.64
8.34
Price/Median PS Value 1.30
GNMK's Price/Median PS Value is ranked higher than
79% of the 523 Companies
in the Global Medical Devices industry.

( Industry Median: 1.36 vs. GNMK: 1.30 )
GNMK' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.51
Current: 1.3

0.62
1.51
Earnings Yield (Greenblatt) -9.10
GNMK's Earnings Yield (Greenblatt) is ranked higher than
56% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. GNMK: -9.10 )
GNMK' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.1   Max: 0
Current: -9.1

-9.1
0

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:GNF.Germany,
GenMark Diagnostics, Inc., was incorporated in the State of Delaware in February 2010. The Company is a molecular diagnostics company developing and commercializing its proprietary eSensor detection technology. Its proprietary electrochemical technology enables fast, accurate and highly sensitive detection of up to 72 distinct biomarkers in a single sample. The Company's XT-8 System received 510(k) clearance from the Food and Drug Administration and is designed to support molecular diagnostic tests with a compact and easy-to-use workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified nucleic acid sample, its XT-8 system produces clear results. The Company's XT-8 System supports up to 24 test cartridges, of which each could be run independently, resulting in a highly convenient and flexible workflow for its customers, which are hospitals and reference laboratories. It intends to expand the use of its XT-8 System and diagnostic tests to those reference laboratories and hospitals in the United States which perform a high volume of molecular diagnostic tests. The Company's XT-8 System is an automated molecular diagnostic system that enables reference laboratories and hospitals to perform fast, accurate and easy-to-use molecular diagnostic tests. The XT-8 System, which employs its proprietary electrochemical detection technology, consists of a compact bench-top workstation with an integrated touch screen computer and an analyzer into which the self-contained, disposable test cartridges are inserted. The Company's proprietary eSensor technology is based on the competitive DNA hybridization and electrochemical detection. The Company's test cartridges are self-contained devices specifically programmed and configured for a given diagnostic test. Each test cartridge includes a sample compartment and a plastic cover that forms a hybridization chamber. The Company's XT-8 instrument is a multiplex workstation that has a modular design consisting of a base module and up to three test cartridge-processing towers of eight cartridge slots each. It faces competition in the molecular diagnostic testing markets with testing products and systems developed by public and private companies such as Cepheid, Gen-Probe, Inc., Siemens, Hologic, Inc., Innogenetics, Inc, Luminex Corporation, Nanosphere, Inc., Qiagen NV, Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd., Idaho Technologies and Abbott Diagnostics, a division of Abbott Laboratories. The Company's diagnostic tests also face competition with the LDTs developed by national and regional reference laboratories and hospitals. The design, development, manufacture, testing and sale of its diagnostic products are subject to regulation by numerous governmental authorities, the FDA, and corresponding state and foreign regulatory agencies.
» More Articles for GNMK

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: XPL, GNMK Jul 02 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CEO Buys Highlight: SXL, JBSS, GNMK, CNDO, DCO Jun 30 2012 
Weekly CFO Buys Highlight: Bank Mutual Corp., Heelys Inc., GenMark Diagnostics Inc., Regeneration Te Sep 19 2010 
Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 

More From Other Websites
10-K for GenMark Diagnostics, Inc. Feb 26 2015
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits Feb 25 2015
GenMark Diagnostics reports 4Q loss Feb 24 2015
GenMark Diagnostics reports 4Q loss Feb 24 2015
GenMark Reports Fourth Quarter and Full Year 2014 Results Feb 24 2015
GenMark Diagnostics Inc Earnings Call scheduled for 4:30 pm ET today Feb 24 2015
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition Feb 24 2015
GenMark Reports Fourth Quarter and Full Year 2014 Results Feb 24 2015
Q4 2014 GenMark Diagnostics Inc Earnings Release - After Market Close Feb 24 2015
GenMark Announces Appointment of New Board Members Feb 23 2015
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Financial Statements and Exhibits Feb 23 2015
GenMark Announces Appointment of New Board Members Feb 23 2015
GenMark Diagnostics to Present at Two Upcoming Investor Conferences Feb 18 2015
GenMark Diagnostics to Present at Two Upcoming Investor Conferences Feb 17 2015
3 Med-Instrument Stocks Poised to Gain this Earnings Season - Earnings ESP Feb 09 2015
Will Waters (WAT) Surprise Q4 Earnings on Innovations? - Analyst Blog Jan 23 2015
GE Capital Agents $40 Million Credit Facility for GenMark Diagnostics Jan 13 2015
GENMARK DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of... Jan 12 2015
GenMark Announces Completion of ePlex™ Development and Preliminary Q4 Financial Results Jan 12 2015
GenMark Announces Completion of ePlex™ Development and Preliminary Q4 Financial Results Jan 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK